Obstructive Sleep Apnea (OSA) - Pipeline Insight, 2025

DelveInsight’s, “Obstructive Sleep Apnea (OSA) - Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 21+ pipeline drugs in Obstructive Sleep Apnea (OSA) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Obstructive Sleep Apnea (OSA): Understanding

Obstructive Sleep Apnea (OSA): Overview

Obstructive Sleep Apnea (OSA) is a sleep- related breathing disorder in which there is repeated obstruction to the upper airway, while the person is sleeping. Obstructive sleep apnea is when something blocks part or all of the upper airway while a person is asleep. The diaphragm and chest muscles have to work harder to open airway and pull air lungs. Breath can become very shallow, or may even stop breathing briefly. The person usually start to breathe again with a loud gasp, snort, or body jerk.

Individuals with obstructive sleep apnea (OSA) often exhibit several characteristic warning signs. One of the most common indicators is loud, persistent snoring, which is accompanied by episodes of shallow breathing (hypopnea) and complete breathing pauses (apnea) that last longer than ten seconds during sleep. Other common warning signs include daytime sleepiness or fatigue, dry mouth or sore throat upon waking, morning headaches, difficulty concentrating, forgetfulness, depression, or irritability, as well as night sweats, restlessness during sleep, and gastroesophageal reflux disease (GERD). These symptoms are indicative of the disrupted sleep patterns and airway obstruction that are hallmarks of obstructive sleep apnea, and should prompt individuals to seek medical evaluation and treatment.

Objective testing method is employed to make an initial diagnosis of some patients who complain of snoring and excessive day time sleepiness.

• Epworth sleepiness scale is used to gauge the extent of day time sleepiness with the help of a questionnaire answered by the patient.
• Nocturnal polysomnography is considered the best evaluation tool for diagnosing obstructive sleep apnea. This tool helps in assessing the patient in a sleep laboratory by applying several physiological parameters when the patient is asleep.

Apneic events can then be documented based on chest wall movement with no air flow and low oxygen levels in the blood (measured by oxy-hemoglobin desaturations). A respiratory disturbance index (RDI) is then calculated and expressed as the number of abnormal respiratory events per hour of sleep. The cut-off point adopted by a few sleep laboratories, in the case of continuous positive airway pressure, is RDI of 20 episodes per hour.

Treatment focuses on rectifying nighttime breathing, in order to positively impact the problems of loud snoring and daytime sleepiness. This will also cut the risks of associated medical conditions, like high blood pressure, heart attack and stroke. Treatment for Obstructive Sleep Apnea also helps patients with maintenance of appropriate weight. Obese victims of OSA find immense relief with weight loss.

""Obstructive Sleep Apnea (OSA) - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Obstructive Sleep Apnea (OSA) pipeline landscape is provided which includes the disease overview and Obstructive Sleep Apnea (OSA) treatment guidelines. The assessment part of the report embraces, in depth Obstructive Sleep Apnea (OSA) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Obstructive Sleep Apnea (OSA) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Obstructive Sleep Apnea (OSA) R&D. The therapies under development are focused on novel approaches to treat/improve Obstructive Sleep Apnea (OSA).

Obstructive Sleep Apnea (OSA) Emerging Drugs Chapters

This segment of the Obstructive Sleep Apnea (OSA) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Obstructive Sleep Apnea (OSA) Emerging Drugs

• Tirzepatide: Eli Lilly and Company

Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist. Tirzepatide is a single novel molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones. GIP is a hormone that may complement the effects of GLP-1 receptor agonists. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure therefore resulting in weight reductions, and when combined with GLP-1 receptor agonism, may result in greater effects on markers of metabolic dysregulation such as body weight, glucose and lipids. Currently, the drug is in the Phase III stage of clinical trial evaluation for the treatment of Obstructive Sleep Apnea (OSA).

• Sulthiame: Desitin Arzneimittel GmbH

Sulthiame is an investigational drug being developed by Desitin Arzneimittel GmbH. The drug is a carbonic anhydrase inhibitor, demonstrating a significant efficacy in reducing apneas during sleep. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Obstructive sleep apnea.

• GAL-475: Neurim Pharmaceuticals

GAL-475 is a novel therapeutic agent for the treatment of sleep apnea syndromes. The primary site of action for GAL-475 appears to be at the level of the carotid body, a peripheral polymodal chemosensory organ, located at the carotid bifurcation, responsible for sensing changes in partial pressures of O2, CO2 or pH, and activating the brainstem respiratory center to produce hyperventilation. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Obstructive Sleep Apnea (OSA).

Further product details are provided in the report……..

Obstructive Sleep Apnea (OSA): Therapeutic Assessment

This segment of the report provides insights about the different Obstructive Sleep Apnea (OSA) drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Obstructive Sleep Apnea (OSA)

There are approx. 20+ key companies which are developing the therapies for Obstructive Sleep Apnea (OSA). The companies which have their Obstructive Sleep Apnea (OSA) drug candidates in the most advanced stage, i.e. Phase III include, Eli Lilly and Company.

• Phases

DelveInsight’s report covers around 21+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Obstructive Sleep Apnea (OSA) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Obstructive Sleep Apnea (OSA): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Obstructive Sleep Apnea (OSA) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Obstructive Sleep Apnea (OSA) drugs.

Obstructive Sleep Apnea (OSA) Report Insights

• Obstructive Sleep Apnea (OSA) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Obstructive Sleep Apnea (OSA) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Obstructive Sleep Apnea (OSA) drugs?
• How many Obstructive Sleep Apnea (OSA) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Obstructive Sleep Apnea (OSA)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Obstructive Sleep Apnea (OSA) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Obstructive Sleep Apnea (OSA) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Eli Lilly and Company
• Apnimed
• Desitin Arzneimittel GmbH
• Takeda
• Neurim Pharmaceuticals
• Enalare Therapeutics
• SciSparc
• Bayer
• Incannex Healthcare

Key Products

• Tirzepatide
• AD-109
• Sulthiame
• TAK-925
• Gal-475
• ENA-002
• SCI-110
• BAY-2586116
• IHL-42X